Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | TACR2 | P21452 | 1/20 | 0.61 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098313 | 0.85 | TACR3 (0.73) | TACR3CYP3A4TACR2DHODHPTGFR | |
| SCHEMBL4230491 | 0.84 | TACR3 (0.72) | TACR3CYP3A4TACR2DHODHPTGFR | |
| SCHEMBL3899657 | 0.82 | TACR3 (0.70) | TACR3TACR2DHODH | |
| SCHEMBL3959255 | 0.82 | TACR3 (0.68) | TACR3CYP3A4TACR2DHODH | |
| SCHEMBL6268728 | 0.80 | TACR3 (0.66) | TACR3CYP3A4TACR2 | |
| SCHEMBL3961862 | 0.79 | TACR3 (0.67) | TACR3CYP3A4TACR2DHODH | |
| SCHEMBL8271391 | 0.79 | TACR3 (0.65) | TACR3CYP3A4TACR2DHODH | |
| SCHEMBL29864839 | 0.79 | TACR3 (0.65) | TACR3CYP3A4TACR2DHODH | |
| SCHEMBL28844477 | 0.79 | TACR3 (0.65) | TACR3CYP3A4TACR2DHODH | |
| SCHEMBL3963301 | 0.79 | TACR3 (0.81) | TACR3CYP3A4TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482457-B2 | Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands | MERCK SHARP & DOHME | 2009-01-27 | — | — | US | disclosed |
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | MERCK SHARP & DOHME LTD. (GB) | 2008-04-24 | — | — | US | disclosed |
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-04-27 | — | — | US | disclosed |
| EP-1594844-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072045-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | HRH4, HRH3, HRH2 | TACR3 8/4885CYP3A4 968/4885TACR2 6/4885 |
| US-20080096885-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR3, TACR2, TAC3 | TACR3 1/4885CYP3A4 1590/4885TACR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.